Live Attenuated Influenza Viruses Containing NS1 Truncations as Vaccine Candidates against H5N1 Highly Pathogenic Avian Influenza
Open Access
- 15 February 2009
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 83 (4), 1742-1753
- https://doi.org/10.1128/jvi.01920-08
Abstract
Due to the high mortality associated with recent, widely circulating strains of H5N1 influenza virus in poultry, the recurring introduction of H5N1 viruses from birds to humans, and the difficulties in H5N1 eradication by elimination of affected flocks, an effective vaccine against HPAI (highly pathogenic avian influenza) is highly desirable. Using reverse genetics, a set of experimental live attenuated vaccine strains based on recombinant H5N1 influenza virus A/Viet Nam/1203/04 was generated. Each virus was attenuated through expression of a hemagglutinin protein in which the polybasic cleavage site had been removed. Viruses were generated which possessed a full-length NS1 or a C-terminally truncated NS1 protein of 73, 99, or 126 amino acids. Viruses with each NS genotype were combined with a PB2 polymerase gene which carried either a lysine or a glutamic acid at position 627. We predicted that glutamic acid at position 627 of PB2 would attenuate the virus in mammalian hosts, thus increasing the safety of the vaccine. All recombinant viruses grew to high titers in 10-day-old embryonated chicken eggs but were attenuated in mammalian cell culture. Induction of high levels of beta interferon by all viruses possessing truncations in the NS1 protein was demonstrated by interferon bioassay. The viruses were each found to be highly attenuated in a mouse model. Vaccination with a single dose of any virus conferred complete protection from death upon challenge with a mouse lethal virus expressing H5N1 hemagglutinin and neuraminidase proteins. In a chicken model, vaccination with a single dose of a selected virus encoding the NS1 1-99 protein completely protected chickens from lethal challenge with homologous HPAI virus A/Viet Nam/1203/04 (H5N1) and provided a high level of protection from a heterologous virus, A/egret/Egypt/01/06 (H5N1). Thus, recombinant influenza A/Viet Nam/1203/04 viruses attenuated through the introduction of mutations in the hemagglutinin, NS1, and PB2 coding regions display characteristics desirable for live attenuated vaccines and hold potential as vaccine candidates in poultry as well as in mammalian hosts.Keywords
This publication has 33 references indexed in Scilit:
- An Inhibitory Activity in Human Cells Restricts the Function of an Avian-like Influenza Virus PolymeraseCell Host & Microbe, 2008
- A combination in-ovo vaccine for avian influenza virus and Newcastle disease virusVaccine, 2008
- Growth of H5N1 Influenza A Viruses in the Upper Respiratory Tracts of MicePLoS Pathogens, 2007
- A New Generation of Modified Live-Attenuated Avian Influenza Viruses Using a Two-Strategy Combination as Potential Vaccine CandidatesJournal of Virology, 2007
- Multiple Anti-Interferon Actions of the Influenza A Virus NS1 ProteinJournal of Virology, 2007
- Avian Influenza Virus (H5N1): a Threat to Human HealthClinical Microbiology Reviews, 2007
- Amelioration of Influenza Virus Pathogenesis in Chickens Attributed to the Enhanced Interferon-Inducing Capacity of a Virus with a Truncated NS1 GeneJournal of Virology, 2007
- Inhibition of Retinoic Acid-Inducible Gene I-Mediated Induction of Beta Interferon by the NS1 Protein of Influenza A VirusJournal of Virology, 2007
- Vaccination of Pigs against Swine Influenza Viruses by Using an NS1-Truncated Modified Live-Virus VaccineJournal of Virology, 2006
- Engineered viral vaccine constructs with dual specificity: Avian influenza and Newcastle diseaseProceedings of the National Academy of Sciences of the United States of America, 2006